Lupus & antiphospholipid syndrome
GLP-1 receptor agonists in systemic lupus erythematosus: a scoping review
Authors' conclusion
Collectively, findings from the included studies suggest that GLP-1 RAs may provide metabolic and anti-inflammatory benefits in SLE with an acceptable safety profile; however, clinical data specific to SLE remain limited
Study context
- Population
- Studies evaluating GLP-1 RAs in systemic lupus erythematosus (SLE) (PubMed, Embase, Scopus, Cochrane Library, inception to April 2026)14 studies
Methodological detailsPRISMA-guided
- PRISMA-guided
Main finding
As reported in the abstract
- GLP-1 RAs demonstrated consistent anti-inflammatory, metabolic and endothelial effects relevant to SLE
- Mechanistic data suggest reductions in cytokine signalling, oxidative stress and macrophage activation
- SLE-specific evidence largely from small observational cohorts, retrospective analyses and isolated case reports; much supportive data preclinical or extrapolated from broader rheumatic disease populations
- Included studies: narrative reviews, mechanistic analyses, editorials and case reports
Safety
- Drug-induced lupus reported in case studies
- 2
- Acceptable safety profile in autoimmune populations
Original publication
GLP-1 receptor agonists in systemic lupus erythematosus: a scoping review. RMD Open. Published 16 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →